Skip to main content
SpringerLink
Log in

Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

To investigate the incidence of adverse events (AEs) following single and multiple administrations of I-131 metaiodobenzylguanidine (MIBG) therapy for inoperable pheochromocytomas and paragangliomas (PPGLs).

Methods

A single-center retrospective study was conducted on patients with inoperable PPGLs who underwent I-131 MIBG therapy between January 2000 and December 2020. A total of 28 patients with available electronic medical records were included. The treatment consisted of a single intravenous administration of 150 mCi (5.55 GBq) of I-131 MIBG. We evaluated the first MIBG treatment and repeated MIBG treatments performed within 200 days of the previous treatment. AEs for each treatment were evaluated using CTCAE version 4.0, and the statistical analysis was conducted at a significance level of p < 0.05. Objective response based on RECIST 1.1 criteria and biochemical response based on urinary catecholamines were assessed.

Results

The study included a total of 63 administrations, consisting of 28 single administrations (SAs), including the first administration for all 28 cases, and 35 multiple administrations (MAs), which included the second or later administrations. Hematological AEs were evaluable for 23 SAs and 29 MAs. Grade 3 or higher leukopenia occurred in 9.8% of all administrations, and Grade 3 or higher lymphopenia in 23.5%; both were manageable through observation. There were no significant differences in clinical AE Grades 1–2 (p = 0.32), hematological AE Grades 1–2 (p = 0.22), or hematological AE Grades 3–4 (p = 0.12) between MAs and SAs. Statistical analysis for each type of AE revealed significant increases in leukopenia (p < 0.01) and lymphopenia (p = 0.04). No significant difference in anemia, thrombocytopenia, or neutropenia was observed between MAs and SAs. There was no significant increase in the incidence rate of Grade 3 or higher hematological AEs for any of the parameters. The objective response rate was 0% for SAs and 36% for MAs. Biochemical response rates were 18% for SAs and 67% for MAs.

Conclusion

In I-131 MIBG therapy for PPGLs, multiple administrations significantly increased only Grade 1 or 2 lymphopenia and leukopenia compared to single administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

All data used to support the findings of this study are included within the article.

References

  1. Tishler AS, de Krijger RR, Gill A, et al.: WHO classification of tumours of the adrenal medulla and extra-adrenal paraganglia. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J. (eds) WHO Classifications of Tumours of Endocrine Organs. 4th edition IARC Press, Lyon, 2017, p. 180-89.

  2. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (2008) EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. Springer Verlag; p. 1039–47

  3. Wieland DM, Swanson DP, Brown LE, Beierwaltes WH. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med. 1979;20:155–8.

    CAS  PubMed  Google Scholar 

  4. Kinuya S, Yoshinaga K, Higuchi T, Jinguji M, Kurihara H, Kawamoto H. Draft guidelines regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors: Guideline Drafting Committee for Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine. Ann Nucl Med. 2015;29:543–552.

    Article  CAS  PubMed  Google Scholar 

  5. Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, Higuchi T, et al. (2019) A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. Sci Rep 9

  6. Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, Kayano D, et al. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma. Ann Nucl Med. 2022;36:267–78.

    Article  CAS  PubMed  Google Scholar 

  7. Yoshinaga K, Oriuchi N, Wakabayashi H, Tomiyama Y, Jinguji M, Higuchi T, et al. Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Endocr J. 2014;61:1171–80.

    Article  CAS  PubMed  Google Scholar 

  8. Shilkrut M, Bar-Deroma R, Bar-Sela G, Berniger A, Kuten A. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: Single center experience. Am J Clin Oncol Cancer Clin Trials. 2010;33:79–82.

    Article  CAS  Google Scholar 

  9. Navalkissoor S, Alhashimi DM, Quigley AM, Caplin ME, Buscombe JR. Efficacy of using a standard activity of 131I-MIBG therapy in patients with disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010;37:904–12.

    Article  PubMed  Google Scholar 

  10. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131i]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60:623–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EPM (2014) 131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: Systematic review and meta-analysis. Clin Endocrinol (Oxf). Blackwell Publishing Ltd., p. 487–501

  13. Yoshinaga K, Abe T, Okamoto S, Uchiyama Y, Manabe O, Ito YM, et al. Effects of Repeated 131I-Meta-Iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patients with Metastatic Neuroendocrine Tumors. J Nucl Med. 2021;62:685–94.

    Article  CAS  PubMed  Google Scholar 

  14. Takenaka J, Watanabe S, Abe T, Tsuchikawa T, Takeuchi S, Hirata K, et al. (2023) Predictive Factors of Early 18F-Fluorodeoxyglucose-Positron Emission Tomography Response to [131I] Metaiodobenzylguanidine Treatment for Unresectable or Metastatic Pheochromocytomas and Paragangliomas. Neuroendocrinology 1–11

  15. Takenaka J, Watanabe S, Abe T, Hirata K, Uchiyama Y, Kimura R, et al. Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL). Ann Nucl Med. 2023;37:10–17.

    Article  CAS  PubMed  Google Scholar 

  16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  PubMed  Google Scholar 

  17. Wakabayashi H, Taki J, Inaki A, Nakamura A, Kayano D, Fukuoka M, et al. Prognostic values of initial responses to low-dose 131I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma. Ann Nucl Med. 2013;27:839–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012;67:1025–39.

    Article  PubMed  Google Scholar 

  19. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, et al. Malignant pheochromocytomas and paragangliomas: A phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci. Blackwell Publishing Inc.; 2006. p. 465–90

  20. Kotecka-Blicharz A, Hasse-Lazar K, Handkiewicz-Junak D, Gawlik T, Pawlaczek A, Oczko-Wojciechowska M, et al. 131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours - a single-centre study. Endokrynol Pol. 2018;69:246–51.

    Article  CAS  PubMed  Google Scholar 

  21. Gedik GK, Hoefnagel CA, Bais E, Valdés Olmos RA. 131I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35:725–33.

    Article  CAS  PubMed  Google Scholar 

  22. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131i-meta-iodobenzylguanidine (131I-mIBG). Clin Endocrinol (Oxf). 2001;55:47–60.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We express deep gratitude to all the staff members, nurses, and radiological technologists involved in the medical care of the patients in this study.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Hokkaido University Hospital, Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan

    Naoto Wakabayashi, Shiro Watanabe, Junki Takenaka & Kenji Hirata

  2. Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan

    Naoto Wakabayashi, Rina Kimura, Keita Sakamoto & Kohsuke Kudo

  3. Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Kita15, Nishi7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan

    Naoto Wakabayashi, Shiro Watanabe, Junki Takenaka, Kenji Hirata, Rina Kimura, Keita Sakamoto & Kohsuke Kudo

  4. Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Kita15, Nishi7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan

    Takashige Abe & Nobuo Shinohara

Authors
  1. Naoto Wakabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiro Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashige Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junki Takenaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenji Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rina Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keita Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobuo Shinohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kohsuke Kudo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shiro Watanabe.

Ethics declarations

Conflict of interest

The authors have no potential conflicts of interest related to the content of this paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wakabayashi, N., Watanabe, S., Abe, T. et al. Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis. Ann Nucl Med (2024). https://doi.org/10.1007/s12149-024-01928-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12149-024-01928-2

Keywords

Search

Navigation